Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Erich Fischer
AddedFeb 15, 2024
UpdatedMay 31, 2026
Erich Fischer

Erich Fischer

Co-Founder, Civetta Therapeutics

CrunchbaseThe Org

Erich Fischer's Career

Civetta Therapeutics
Civetta Therapeutics

Cambridge, MA, US

Co-Founder
Jengu Therapeutics
Jengu Therapeutics

San Diego, CA, US

Co-Founder
Neomorph
Neomorph

San Diego, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Erich Fischer's Career

Civetta Therapeutics
Civetta Therapeutics
Series A$53M392019Cambridge, MA, US
Co-Founder

Leadership at Civetta Therapeutics

Christopher RobertsChristopher RobertsCEO
William SellersWilliam SellersCo-Founder

Similar to Civetta Therapeutics

Cedilla TherapeuticsCedilla TherapeuticsCambridge, MA, USTherapeuticsest. 2018Cedilla TherapeuticsCambridge, MA, US · est. 2018

Cedilla Therapeutics: A Massachusetts-based biotech firm innovating small molecule disease treatments.

Series B · $138.8M45
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Traws PharmaTraws PharmaNewtown, PA, USCancer Treatmentsest. 1998Traws PharmaNewtown, PA, US · est. 1998

US-based Onconova Therapeutics, Inc. pioneers novel cancer treatments through small molecule drug discovery.

Public · $177.9M17
Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18
Jengu Therapeutics
Jengu Therapeutics
Seed$5M62020San Diego, CA, US
Co-Founder

Leadership at Jengu Therapeutics

Benjamin NeelBenjamin NeelCo-Founder

Similar to Jengu Therapeutics

Signet TherapeuticsSignet TherapeuticsNewton, MA, USCancer Drugsest. 2020Signet TherapeuticsNewton, MA, US · est. 2020

Signet Therapeutics, a biopharmaceutical startup, innovates targeted cancer drugs using unique disease models.

Seed · $20M30
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
GeneiusGeneiusNatick, MA, USCancer Treatmentest. 1998GeneiusNatick, MA, US · est. 1998

Geneius Biotechnology pioneers unique T cell immunotherapy for cancer, translating innovative treatments from lab to patient.

Seed · $5.4M5
Juvena TherapeuticsJuvena TherapeuticsPalo Alto, CA, USTherapeuticsest. 2017Juvena TherapeuticsPalo Alto, CA, US · est. 2017

Juvena Therapeutics: A biopharmaceutical platform for novel protein-based therapeutics discovery.

Series A · $49.2M11
Neomorph
Neomorph
Series A$109M622020San Diego, CA, US
Co-Founder

Leadership at Neomorph

Philip ChamberlainPhilip ChamberlainCo-Founder
Scott ArmstrongScott ArmstrongCo-Founder
Benjamin EbertBenjamin EbertCo-Founder

Similar to Neomorph

76Bio76BioNew York City, NY, USProtein Degradersest. 202076BioNew York City, NY, US · est. 2020

76Bio, a NY-based biotech firm, pioneers targeted protein degraders for life-threatening diseases.

Series A · $10M16
NurixNurixSan Francisco, CA, USDrugsest. 2012NurixSan Francisco, CA, US · est. 2012

San Francisco-based Nurix Therapeutics develops novel drugs, harnessing natural processes to treat cancer.

Public · $370.9M297
Innovo TherapeuticsInnovo TherapeuticsSan Diego, CA, USAnti-Cancer Drugsest. 2021Innovo TherapeuticsSan Diego, CA, US · est. 2021

San Diego-based Innovo Therapeutics develops anti-cancer drugs targeting protein breakdown.

Seed · $200M11
PlexiumPlexiumSan Diego, CA, USTherapeuticsest. 2018PlexiumSan Diego, CA, US · est. 2018

Plexium, a San Diego-based med-tech firm, pioneers first-in-class therapeutics via E3 ligases modulation.

Series B · $165M94

Erich Fischer's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Erich Fischer

Jeffrey EskoJeffrey EskoCo-Founder · CoviCept TherapeuticsPhilip GordtsPhilip GordtsCo-Founder · CoviCept TherapeuticsDavid TingDavid TingCo-Founder · TellBioSamy MerouehSamy MerouehCo-Founder · Kovina TherapeuticsFletcher FotiFletcher FotiCo-Founder · PopulusMichael JungMichael JungCo-Founder · Pelage Pharma